GlassScriptPhysician profile
Thomas John Yeagley
NPI 1558471896
$1,579.23
in general payments reported to CMS, 2019-2025
26 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $197 · 2021: $136 · 2022: $302 · 2023: $268 · 2024: $202 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.23 | 2019-2023 | Orilissa |
| Coopersurgical, INC. | $125.95 | 2020-2025 | Paragard T 380a |
| Astellas Pharma US INC | $122.00 | 2019-2025 | Veozah, Myrbetriq |
| Biogen, INC. | $113.98 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $92.31 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $85.52 | 2019-2025 | |
| Amgen INC. | $65.59 | 2020-2024 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $64.54 | 2020-2024 | Novasure, Acessa Provu System |
| Dexcom, INC. | $62.19 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $55.60 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $45.57 | 2024-2025 | |
| Myovant Sciences INC. | $45.28 | 2022 | |
| Sumitomo Pharma America, INC. | $41.07 | 2023 | Myfembree |
| Lupin INC. | $29.55 | 2019 | |
| Coloplast Corp | $26.31 | 2020-2023 | Altis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $24.80 | 2024 | |
| Organon LLC | $23.74 | 2022-2024 | |
| Solventum Corporation | $23.63 | 2024 | Prevena |
| Avanos Medical | $22.77 | 2019 | |
| Roche Diagnostics Corporation | $21.41 | 2019 | |
| Agile Therapeutics, INC. | $19.41 | 2021 | |
| Mayne Pharma Commercial LLC | $19.23 | 2022 | |
| Novo Nordisk INC | $14.72 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.76 | 2019 | |
| Merck Sharp & Dohme LLC | $12.08 | 2020 | |
| Meditrina | $7.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Yeagley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.